Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Extension Study of Balinatunfib in Adults With Crohn's Disease or Ulcerative Colitis
NCT07222189Phase 2Terminated
- Sponsor
- Sanofi
- Start
- May 2026
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of balinatunfib in Crohn's disease, ulcerative colitis (UC), sponsored by Sanofi. Started May 2026; status: terminated.
02
Drugs
balinatunfib
03
Conditions
Crohn's diseaseulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07222189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07222189.